Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related CPHD
Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid
Benzinga's Top Downgrades
Related ABT
Weed Vs. Opioids: Nontraditional And Traditional Biotech Take On Wall Street, But Who's Winning?
Global Market For Medical Implants To Hit Nearly $27 Billion In 5 Years
Palisades Hudson Asset Management, L.P. Buys iShares Core S&P Small-Cap, iShares S&P ... (GuruFocus)

Analysts at Piper Jaffray downgraded Cepheid (NASDAQ: CPHD) from “overweight” to “neutral.” Cepheid's shares closed at $34.09 yesterday. Cepheid's trailing-twelve-month ROE is -12.52%.

Analysts at Deutsche Bank downgraded Abbott Laboratories (NYSE: ABT) from “buy” to “hold.” Abbott's shares closed at $33.27 yesterday. Abbott's PEG ratio is 0.51.

Analysts at Goldman Sachs downgraded Wells Fargo & Company (NYSE: WFC) from “buy” to “neutral.” Wells Fargo's shares closed at $34.76 yesterday. Wells Fargo's trailing-twelve-month profit margin is 23.18%.

Raymond James downgraded First Solar (NASDAQ: FSLR) from “market perform” to “underperform.” First Solar's shares closed at $34.41 yesterday. First Solar's trailing-twelve-month ROA is 2.17%.

Latest Ratings for CPHD

DateFirmActionFromTo
Sep 2016BairdDowngradesOutperformNeutral
Sep 2016CitigroupDowngradesBuyNeutral
Sep 2016BairdMaintainsOutperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (CPHD + ABT)

View Comments and Join the Discussion!